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Introduction
The term ‘‘prion’’ was originally coined by Prusiner to explain
the unusual infectious agent in transmissible spongiform enceph-
alopathies (TSEs, also known as prion disease) [1]. Now the term
has expanded to include a growing list of fungal proteins that
stably maintain an atypical self-propagating conformation and
epigenetically modify a variety of cellular processes [2]. Although
fungal prions and the TSE agent share the capability of
maintaining an atypical self-propagating conformation, fungal
prions distinctly differ from the TSE agent in several aspects [3].
Thus far, the TSE agent is the only prion that behaves as a bona
fide infectious agent, having an infectious cycle, capable of
transmitting horizontally (among a community) and causing
epidemic outbreaks [3]. The discussion in this article will be
focused on mammalian prion, and the term ‘‘prion’’ specifically
refers to the infectious TSE agent.
Prion Is a Protein Conformation-Based Infectious
Agent
Prions were defined as small proteinaceous infectious particles
that cause TSEs [1], a group of fatal neurodegenerative diseases
including Creutzfeldt-Jakob disease (CJD) in human, scrapie in
sheep, bovine spongiform encephalopathy (BSE) in cattle, and
chronic wasting disease (CWD) in deer and elk. Prion protein (PrP)
is an N-linked glycoprotein tethered to lipid membranes via a
glycophosphatidylinositol (GPI)-anchor, widely expressed in var-
ious tissues and highly enriched in the central nervous system. The
host-encoded normal prion protein (PrP
C)i sa-helical rich, soluble
in mild detergents, sensitive to protease digestion, and releasable
from lipid membrane by phosphatidylinositol-specific phospholi-
pase C (PI-PLC) digestion. During prion disease, a portion of PrP
converts to an aberrant conformational isoform called PrP
Sc,
which is mostly b-sheeted, highly aggregated, protease-resistant,
and unable to be released from lipid membrane by PI-PLC
digestion.
The prion hypothesis postulates that, because of its self-
propagating property, PrP
Sc isoform seeds the conversion of
normal PrP
C to the pathogenic PrP
Sc and causes the disease. The
self-propagating characteristic of disease-associated PrP
Sc has been
demonstrated by cell-free conversion assay and serial protein
misfolding cyclic amplification (sPMCA) [4,5]. The simultaneous
propagation of protease-resistant PrP
Sc and prion infectivity in
sPMCA provides strong evidence supporting the prion hypothesis
[5]. Because crude brain homogenate is used in sPMCA for prion
propagation, it is difficult to conclusively establish a causal
relationship between PrP
Sc and prion disease.
Clearly establishing that PrP
Sc, an altered conformational PrP
isoform, is the causative agent for prion disease has been a
challenge for the prion field for decades, mainly because PrP
Sc is
highly aggregated, preventing it from being purified to homoge-
neity using conventional biochemical methods. An alternative
approach is to reconstitute prion infectivity in vitro with defined
components. Amyloid fibers formed in vitro with bacterially
expressed recombinant PrP (recPrP) have been shown to contain
limited prion infectivity [6–8]. Infectious prions have been formed
through unseeded sPMCA with native PrP
C purified from brains
[9] or recPrP [10] as substrate, or by converting recPrP into an
infectious conformer in sPMCA seeded with partially purified
PrP
Sc [11]. More importantly, the infectivity of prions generated
via sPMCA has been demonstrated by causing bona fide prion
disease in wild-type animals [9,10,11]. Because bacterially
expressed recPrP does not contain any eukaryotic genetic
informational molecules, generating prion infectivity with recPrP
[10–12] is generally accepted as the most stringent proof of prion
hypothesis.
Cofactors Promote Prion Propagation
A key concept of the prion hypothesis is that prion is a self-
propagating PrP conformer, which elicits the conversion of host-
encoded normal PrP
C to pathogenic PrP
Sc. This self-propagating
property of PrP conformers is best demonstrated by in vitro assays.
Recombinant PrP in amyloid fibers represents a self-propagating
conformational state that is distinct from normal PrP
C, but recPrP
in amyloid fibers is generally without the biochemical hallmark of
PrP
Sc, C-terminal proteinase K (PK)-resistance. The in vitro assays
that propagate the classic PK-resistant PrP
Sc conformation include
cell-free conversion assay and sPMCA [4,5]. The cell-free
conversion uses partially purified PrP
Sc as seed and PrP
C purified
from cultured cells as substrate, which is far less efficient than
sPMCA that employs crude brain homogenates. The difference
between two assays suggests the presence of factors in the brain
homogenates that promote efficient prion propagation. Polya-
nions, such as RNA molecules and proteoglycans, have been
identified as one type of cofactors in the brain homogenate that
enhance prion propagation [13,14]. Lipids are another type of
cofactors that promote prion propagation in cell-free conversion
assay [15] and in propagating recombinant prions via sPMCA
[10].
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Always Correlate to Prion Infectivity
Prion infectivity obviously depends on the seeding or self-
propagating property of PrP conformers. However, a PrP
conformer with seeding or self-propagating capability does not
necessarily contain prion infectivity in vivo, that is, cause
spongiform encephalopathy in animals. This notion is exemplified
by PrP amyloid fiber, which clearly contains a strong seeding or
self-propagating capability, but does not have a strong association
with in vivo infectivity. The PrP amyloid fibers in the brain tissues
of a familial prion disease patient induce a prominent PrP-amyloid
accumulation in ‘‘humanized’’ knock-in mice carrying the same
mutation, demonstrating in vivo seeding or self-propagating
property of PrP amyloid fibers [16]. However, a lack of
spongiform encephalopathy or any neurological disorders during
the life span of these PrP amyloid–bearing mice suggests a
dissociation of prion infectivity from seeding capability [16].
Similarly, in vitro generated recPrP amyloid fibers contain a strong
in vitro seeding capability, but very low prion infectivity [6–8].
Even with PK-resistant PrP conformers, their abilities to propagate
the PK-resistant conformation in sPMCA do not always associate
with in vivo prion infectivity [17].
Collectively, the seeding or self-propagating property of a prion
is essential for its infectivity, but not all PrP conformers with
seeding or self-propagating capability are competent to cause
prion disease in animals.
Cofactors Appear to Play an Important Role in
Prion Infectivity
The role of cofactors in prion infectivity remains to be clarified,
but comparing several in vitro reconstituted infectious prions
indicates that they play an important role in prion infectivity.
When infectious prions were formed with recPrP or purified PrP
C
via sPMCA in the presence of lipid and RNA as cofactors, the
newly formed prions contain high infectivity [9,10]. When
recombinant prions were formed via seeded sPMCA in the
absence of any mammalian cofactors, the prion infectivity is lower
but still sufficient to cause disease in wild-type animals [11].
Notably, the buffer used in cofactor-free sPMCA contains SDS
and Triton X-100 detergents, which are similar to lipid in
biophysical properties and may partially replace the function of a
lipid cofactor. The in vitro recPrP amyloid fiber formation,
however, is in a partially denaturing buffer and completely without
any cofactors. Interestingly, recPrP amyloid fibers contain very low
infectivity, fail to cause disease in wild-type animals, and only
cause disease with prolonged incubation times in PrP overex-
pressing mice [6,7]. The limited infectivity of recPrP amyloid
fibers in animals could be explained by binding to cofactors in
vivo, leading to further PrP adaptations and conformational
changes [18]. Nevertheless, the comparison of in vitro reconsti-
tuted prions indicates that the presence of cofactor enhances in
vivo prion infectivity.
Mechanism of Cofactor in Prion Propagation and
Infectivity
To date, two types of cofactors, lipids and polyanions, are
identified as influencing prion propagation and infectivity, but the
precise mechanism remains unclear. It can be envisioned that
cofactors may act on several steps of PrP conversion. Both
polyanion and lipid bindings alter the normal PrP
C conformation
to increase b-sheet content and PrP aggregation, a conformational
change similar to PrP
C-to-PrP
Sc conversion [19–21]. Thus,
cofactor binding may render the normal PrP
C susceptible to
conversion or simply facilitate PrP
Sc-steered PrP
C conversion.
Alternatively, cofactors may facilitate PrP conversion by concen-
trating both PrP
Sc and PrP
C on the surface of a single lipid vesicle
or a single polyanion molecule. Another possibility could be that
the cofactors stabilize the infectious PrP
Sc conformation by
forming a complex with PrP
Sc and being a part of the infectious
particle.
Both lipids and polyanions enhance prion propagation, yet
polyanion does not appear to be critical for prion infectivity [22].
Lipids, on the other hand, not only influence prion propagation,
but also have a significant impact on prion infectivity. A ,100-fold
increase in prion infectivity has been observed when purified prion
is re-incorporated into liposomes [23]. Therefore, these two types
of cofactors may act on the same or different steps in prion
propagation and infectivity.
Most cofactor-related studies use mouse or hamster prions. It is
well known that prions from different species or different prion
strains have very different properties, which could be due to the
different combinations of various lipid or polyanion molecules. It is
also possible that other types of molecules could serve as cofactors,
contributing to the diverse biological properties of prions. Further
investigation of prion cofactors will help us to gain the insights of
this enigmatic infectious agent, which is essential for us to combat
these devastating diseases.
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